Genomma Lab Announces 2009 Earnings Guidance
Genomma Lab expects to maintain its strategy of brand acquisitions and, ona timely basis, will inform the market on any completed transaction, as wellas the corresponding change to the Company's earnings guidance. As of theclose of the third quarter 2008, the Company had a cash balance andequivalents of Ps. 1,073 million that may be used partially or totally forpotential brand acquisitions.
Genomma Lab will continue its efforts to increase its share in the Mexicanpersonal care and over-the-counter markets. The value of such markets isapproximately Ps. 75 billion(II) and Ps. 19 billion(III), respectively.
Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counterpharmaceuticals and personal care products company in Mexico withinternational presence. Genomma develops, sells and markets a broad range ofpremium branded products, many of which are leaders in the categories in whichthey compete in terms of sales and market share.
Genomma Lab performed its Initial Public Offering in June 2008, through acombined offering (mainly primary) and is listed on the Mexican Stock Exchangeunder the ticker symbol "LAB" (Bloomberg: labb.mx).Web Site: www.genommalab.com (I) EBITDA is defined as Operating Income plus Depreciation and Amortization (II) Source: Euromonitor (2006) (III) Source: Datamonitor (2007) Investor Relations in Mexico City: Tel: +52 (55) 5081 0000 Ext. 4250 E-mail: firstname.lastname@example.org In New York: i-advize Corporate Communications, Inc. Tel: (212) 406-3692 E-mail: email@example.com
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
You May Also Like